



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Ranatunge et al**

Application No: **10/608,333**

Group Art Unit: **1626**

Filed: **June 30, 2003**

Examiner: **T.A. Solola**

For: **Oxime and/or Hydrozone containing Nitrosated and/or Nitrosylated Cyclooxygenase-2 Inhibitors, Compositions and Methods of Uses**

Attorney Docket No: **102258.153 US1**

Commissioner of Patents
PO Box 1450
Alexandria, VA 22313-1450

Transmittal Letter

Enclosed herewith for appropriate consideration by the US Patent Office are:

1. Petition from Requirement for Restriction under 37 CFR § 1.144
2. Information Disclosure Statement, PTO-1449 Form, and cited references.
3. Response and Amendment under 37 CFR § 1.111.

The Commissioner is authorized to charge the fee of \$180 for consideration of the Information Disclosure Statement to Deposit Account No. 08-0219. The Commissioner is authorized to charge any other necessary fees or credit any overpayments to Deposit Account No. 08-0219.

Respectfully submitted

Edward D. Grieff
Registration No. 38,898

Date: May 18, 2005
Wilmer Cutler Pickering Hale and Dorr LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: (202) 942-8453